The expression of BCL-2 is mainly limited to ER-positive breast cancer cells, suggesting a good prognosis and that ER positivity is a necessary condition for endocrine therapy and may be more sensitive to endocrine therapy (5). This evidence concerns the gene BCL2 and breast cancer.